Latest Information Update: 11 Oct 2006
At a glance
- Originator OraPharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stomatitis
Most Recent Events
- 18 Feb 2003 OraPharma has been acquired by Johnson & Johnson
- 11 Sep 2001 Phase-I clinical trials for Stomatitis in USA (Unknown route)